TuftsMedicine

The State of Cost-Effectiveness Analyses on Health Services and Procedures

Ma S, Voehler D, Phillips M, Ollendorf DA, Neumann PJ

Center for the Evaluation of Value and Risk in Health, Tufts Medicine, Boston, MA



OBJECTIVES

- To summarize the number and type of published cost-effectiveness analyses (CEAs) on medical interventions
- To examine the data sources used to inform CEAs on health services and procedures

METHODS


- We summarized both the total volume of studies and types of interventions under investigation
- We examined the primary sources of data on effectiveness for CEAs published in 2021
- We compared the sources of effectiveness data between pharmaceutical and service/procedure CEAs


DATA SOURCE

Tufts Medical Center CEA Registry, 1979-2021




RESULTS





Sources of Effectiveness Data, 2021



Sources of Effectiveness Data, 2021

	Randomized Controlled Trials (RCT) (%)	Non-RCT (%)	Total	Chi Square p-value
Pharmaceutical	255 (72.9)	95 (27.1)	350	<0.001
Service & Procedure	165 (49.3)	170 (50.7)	335	
Total	420	265	685	

CONCLUSION

- In total, pharmaceutical and service/ procedure interventions represented 43% and 42% of CEAs respectively, while pharmaceuticals comprise roughly 15% of health spending
- While the proportion of pharmaceutical and service/ procedure CEAs has remained relatively constant over time, the type and quality of data sources informing these evaluations differs significantly
- Researchers should explore opportunities to promote CEAs of services/ procedures, including through prospective clinical trials and rigorous observational studies for effectiveness data

ACKNOWLEDGEMENT

This research study was supported by Pharmaceutical Research and Manufacturers of America (PhRMA)